to repeated switching to IgE, and the chronic formation of IgE-secreting cells could result in sustained IgE production in these patients.
Although it is not addressed in this study 3 , it is possible that the adaptor function of DOCK8 may also integrate other receptors of innate immunity into BCR signaling. By showing that DOCK8 augments BCR signaling and results in STAT3 activation, Jabara et al. provide critical insights into how innate and adaptive immune signaling cascades are interconnected to ensure the long-lived survival of memory B cells and persistent antibody responses 3 . Thus, characterizing the molecular links that coordinate the activity of these signaling cascades is crucial for understanding the molecular basis of the formation of persistent immunity and the defects observed in patients with immunodeficiency.
of their immunoglobulin genes 9 . SHM and CSR are mediated by the cytosine deaminase AID 10 , and in agreement with published data 1 , Jabara et al. show that DOCK8 is not required for initial BCR signaling events or the induction of AID 3 . In fact, SHM and initial IgG responses are induced in the absence of DOCK8 (ref. 1). That result suggests that DOCK8 is not essential for the generation of switched, IgG-expressing B cells but instead is needed for their long-term survival.
The finding that the initial steps of BCR signaling, when antigen concentrations are probably high, are unaffected suggests that the DOCK8-mediated integration of innate receptor signaling into BCR signaling becomes crucial for the later survival of memory B cells when antigen concentrations decrease. However, although this DOCK8-mediated enhancement of BCR signaling might explain the role of DOCK8 in the survival of switched antigen-specific B cells, it raises the question how this leads to the higher IgE serum concentrations of the DOCK8-deficient patients. A simple answer to this question may be that DOCK8-STAT3 signaling prevents switching to IgE. For the generation of different isotypes, CSR is regulated by various stimuli, of which the activation of STAT6 induced by the receptor for interleukin 4 is key for CSR to IgE 11 . The higher IgE concentrations noted in the absence of the function of DOCK8 or STAT3 suggest that activation of DOCK8-STAT3 signaling interferes, in an as-yet-unknown manner, with the activation of switching to IgE induced by the receptor for interleukin 4 during the generation of antibody responses to pathogens (Fig. 1) 
Don't mess with ERAAP!

Jonathan W Yewdell & Xiuju Lu
Immunosurveillance monitors subversion of the endoplasmic reticulum aminopeptidase ERAAP. ERAAP-deficient cells are killed by T cells that recognize nonclassical major histocompatibility complex class I Qa-1 molecules presenting peptides generated in the absence of ERAAP.
considered a 'junkyard' , encoding molecules that could not pass muster as 'classical' class I molecules, which function mainly to present self and foreign peptides to CD8 + T cells. Truth, however, eventually comes into focus. 'Junk' genes encoding MHC molecules (like 'junk' DNA) are anything but junk, as they encode critical participants in the recognition of viruses and tumors by natural killer (NK) cells, the presentation of lipid antigens, antibody trafficking, iron metabolism and maternal-fetal tolerance 1 . In this issue of Nature Immunology, Nagarajan et al. add another important function to that list 2 . They report that the mouse nonclassical MHC class I molecule Qa-1 presents a peptide generated when the endoplasmic reticulum aminopeptidase ERAAP (ERAP) is inhibited, which allows a substantial subset of CD8 + T cells to monitor the activity of this enzyme dedicated to processing antigens presented by classical MHC class I. affinity and hence their stability as cell-surface complexes with MHC class I molecules 14 . The altered repertoire elicits a robust CD8 + T cell response when wild-type mice are immunized with ERAAP-deficient cells 15 .
What do those T cells recognize? That seemingly esoteric question has yielded an interesting and important answer. Nagarjan et al. have isolated CD8 + T cells that recognize Qa-1 presenting a TAP-dependent ligand generated when ERAAP deficiency is induced genetically or chemically 2 . This recognition does not require the expression of classical MHC class I molecules, the sole source of Qdm. To identify antigenic peptides, the authors heroically screen 2,880 plasmid pools comprising a cDNA library derived from ERAAP-deficient splenic dendritic cells. They transfect each pool into Qa-1-expressing L929 mouse fibroblasts and assess its ability to activate a Qa-1-restricted T cell hybridoma that recognizes ERAAP-deficient cells. They identify three positive pools, each containing a plasmid encoding the 'hypothetical' protein Fam49b. They use a series of truncation plasmids to identify the nine-residue peptide FYAEATPML (FL9) located at positions 190-198 in Fam49b and find that synthetic FL9 peptide activates T cells in a Qa-1-dependent manner at subnanomolar concentrations.
The isolation of naturally processed peptides by HPLC shows that FL9 elutes together with the natural peptide, whose recovery requires the presence of Qa-1. To identify cells that recognize complexes of Qa-1 and FL9 (Qa-1-FL9), Nagarjan et al. find that in contrast to the staining of NK cells by Qa-1 b -Qdm tetramers, NK cells are not stained by Qa-1-FL9 tetramers 2 . Instead, Qa-1-FL9 tetramers stain ~20% of interferon-γ-secreting CD8 + T cells induced by the stimulation of splenocytes with ERAAP-deficient cells, which demonstrates its immunodominant status but also indicates the recognition of other potential peptide ligands. Remarkably, the authors identify CD8 + T cells stained with Qa-1-FL9, most expressing the memory markers CD44 and CD122, in naive C57BL/6 spleens at relatively high frequency. Indicative of their probable function, CD8 + T cells specific for Qa-1-FL9 efficiently kill ERAAP-deficient cells or tumor cells treated with ERAAP inhibitors.
Nagarajan et al. clearly show that immunosurveillance monitors ERAAP activity via the presentation by Qa-1 of at least one peptide whose presentation is eradicated by ERAAP. Although their findings remain to be extended to humans and other vertebrates, several aspects of this system support the proposal of its generality. First, Qa-1 and HLA-E demonstrate considerable functional and structural homology 16 despite their limited amino acid homology. Second, the gene encoding Fam49 by T cells, B cells, NK cells and endothelial cells and is upregulated by proinflammatory cytokines, which also induce the secretion of a soluble form of HLA-E that protects cells from lysis by NK cells 5 . Qa-1 also presents foreign and non-Qdm self peptides to CD8 + T cells 6 . In the case of activated autoreactive CD4 + cells, the presentation of self peptide leads to CD8 + T cell-mediated suppression of autoimmunity 7 .
Early investigation into the proteolytic processing of TAP-independent antigens delivered to the endoplasmic reticulum showed that cells robustly trim amino termini 8 . Biochemical studies led to the identification and cloning of interferon-responsive genes encoding ERAAP in mice and ERAP1 and ERAP2 in humans [9] [10] [11] . The first ascribed function elucidated for ERAAP involved the shedding of cytokine receptors 12 , and ERAAP polymorphism has been linked to human autoimmune diseases 13 . ERAAP-deficient mice present peptides with amino-terminal extensions that diminish their Qa-1 was discovered in 1978 as a lymphocyte marker, but its first distinct function was identified decades later, as a ligand for the NK cell receptor heterodimer CD94-NKG2 (also present on some T cells), on the basis of its presentation of a highly conserved peptide (Qdm 3 ) present in the endoplasmic reticuluminsertion sequence of two of the three classical class I molecules (H-2D and H-2L, but not H-2K) 4 . As the presentation of Qdm requires the entire classical MHC class I pathway (proteasomes, the transporter associated with antigen processing (TAP) and tapasin; Fig. 1 ), Qa-1 serves as a sentinel that directs NK cells to destroy potentially dangerous cells whose MHC class I pathway has been manipulated by pathogens or oncogenesis. Humans have a nearly exact functional homolog in HLA-E, which interacts with the homologous NK cell receptor by presenting a Qdm-like peptide from the signal sequence of many classical HLA class I molecules. HLA-E is expressed (Fam49b(190-198) , or an extended precursor) is generated in the cytosol and transported into the endoplasmic reticulum by TAP in ERAAP-sufficient (ERAAP-WT) cells (left). Cells that synthesize the MHC class I molecule Qa-1 do not present when ERAAP is expressed, either because of its possible destruction by ERAAP in the endoplasmic reticulum, as shown here, or because of a less direct mechanism (for example, losing in a competition with ERAAP-generated peptides). In the absence of ERAAP (ERAAP-deficient (ERAAP-KO) cells; right), ) is delivered to Qa-1 and the Qa-1-FL9 complex is delivered to the cell surface, where it activates specific CD8 + T cells that kill the cell. This prevents pathogens or tumor cells from interfering with ERAAP function to avoid immunosurveillance. It might also be used for other purposes by the immune system, as memory T cells are present in young, specific pathogen-free mice. QFL, Qa-1-FL9; β 2 m, β 2 -microglobulin. 
